Notice of AGM

RNS Number : 4321N

Celadon Pharmaceuticals PLC

31 May 2022

 

Celadon Pharmaceuticals Plc

("Celadon" or the "Company") 

Publication of Annual Report and Notice of Annual General Meeting

Celadon Pharmaceuticals Plc, a leading UK based pharmaceutical company focused on the development and supply of natural cannabis-based medicines, announces that copies of the 2021 Annual Report and Accounts, together with its Notice of 2022 Annual General Meeting ("AGM"), were posted to shareholders today and are available for viewing on the Company's website www.celadonpharma.com .

The Company will be holding its AGM at 4.00pm on Monday 27 June 2022 at the Edgbaston Park Hotel and Conference Centre, 53 Edgbaston Park Road, Birmingham, B15 2RS.

Enquiries:

Celadon Pharmaceuticals Plc
James Short Arthur Wakeley	Via Powerscourt
Canaccord Genuity Limited (Nominated Adviser and Broker)
Andrew Potts / Patrick Dolaghan	[phone]
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil	[phone] [e-mail]

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of natural cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office License to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.

For further information please visit our website www.celadonpharma.com

 

END

 

 

NOABKDBNBBKDKPN